FRED D. LUBLIN
Impact in
- Pathology and Forensic Medicine top 0.01%
- Multiple Sclerosis Research Studies
- Neurology top 0.05%
- Peripheral Neuropathies and Disorders
- Neuroinflammation and Neurodegeneration Mechanisms
Papers in
-
- Multiple Sclerosis Research Studies 200
- Neurology 57
- Peripheral Neuropathies and Disorders 43
- Co-authors
- Stephen C. Reingold (15 shared papers)Chris H. Polman (12 shared papers)Jerry S. Wolinsky (41 shared papers)Alan J. Thompson (7 shared papers)Magnhild Sandberg‐Wollheim (3 shared papers)Paul W O'Connor (13 shared papers)Ludwig Kappos (30 shared papers)Massimo Filippi (4 shared papers)
- Journals
- Neurology (63 papers)Multiple Sclerosis Journal (24 papers)Multiple Sclerosis and Related Disorders (21 papers)Annals of Neurology (18 papers)Journal of Neuroimmunology (13 papers)
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
FRED D. LUBLIN
282 papers receiving 51.9k citations
FRED D. LUBLIN's Hit Papers
Peers
Comparison fields: 5 of 168
- Pathology and Forensic Medicine 39.7k
- Neurology 9.6k
- Rheumatology 5.8k
- Developmental Neuroscience 1.5k
- Neurology 2.9k
Countries citing papers authored by FRED D. LUBLIN
This map shows the geographic impact of FRED D. LUBLIN's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by FRED D. LUBLIN with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites FRED D. LUBLIN more than expected).
Fields of papers citing papers by FRED D. LUBLIN
This network shows the impact of papers produced by FRED D. LUBLIN. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by FRED D. LUBLIN. The network helps show where FRED D. LUBLIN may publish in the future.
Co-authors
The 25 scholars most cited alongside FRED D. LUBLIN, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 287 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria Hit paper breakdown → | 2011 | 8303 |
| 2 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Hit paper breakdown → | 2017 | 6003 |
| 3 | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis Hit paper breakdown → | 2001 | 5835 |
| 4 | Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” Hit paper breakdown → | 2005 | 4306 |
| 5 | New Multiple Sclerosis Phenotypic Classification Hit paper breakdown → | 2014 | 3934 |
| 6 | Defining the clinical course of multiple sclerosis Hit paper breakdown → | 1996 | 3112 |
| 7 | A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis Hit paper breakdown → | 2006 | 2749 |
| 8 | Defining the clinical course of multiple sclerosis Hit paper breakdown → | 2014 | 2543 |
| 9 | Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis Hit paper breakdown → | 2016 | 1537 |
| 10 | Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis Hit paper breakdown → | 2016 | 1474 |
| 11 | Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis Hit paper breakdown → | 2006 | 1099 |
| 12 | Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2014 | 723 |
| 13 | Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED] Hit paper breakdown → | 2002 | 643 |
| 14 | Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial Hit paper breakdown → | 2019 | 580 |
| 15 | 1996 | 401 | |
| 16 | 2009 | 395 | |
| 17 | Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2016 | 373 |
| 18 | 2003 | 357 | |
| 19 | How patients with multiple sclerosis acquire disability Hit paper breakdown → | 2022 | 351 |
| 20 | 1997 | 315 |
About FRED D. LUBLIN
FRED D. LUBLIN is a scholar working on Pathology and Forensic Medicine, Neurology, Immunology, Rheumatology and Oncology, having authored 287 papers that have together received 54.0k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (200 papers), Peripheral Neuropathies and Disorders (43 papers), Polyomavirus and related diseases (18 papers), Systemic Lupus Erythematosus Research (16 papers), Immunotherapy and Immune Responses (16 papers), Rheumatoid Arthritis Research and Therapies (15 papers), Cytokine Signaling Pathways and Interactions (11 papers) and Immune Response and Inflammation (10 papers). The work is most often cited by research in Pathology and Forensic Medicine (39.7k citations), Neurology (9.6k citations), Rheumatology (5.8k citations), Developmental Neuroscience (1.5k citations) and Neurology (2.9k citations). FRED D. LUBLIN has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Stephen C. Reingold, Chris H. Polman, Jerry S. Wolinsky, Alan J. Thompson, Magnhild Sandberg‐Wollheim, Paul W O'Connor, Ludwig Kappos, Massimo Filippi, Brian G. Weinshenker and Eva Kubala Havrdova. Their work appears in journals such as Neurology, Multiple Sclerosis Journal, Multiple Sclerosis and Related Disorders, Annals of Neurology and Journal of Neuroimmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.